BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
Abstract Appendiceal Adenocarcinoma (AA) is a rare gastrointestinal cancer with no FDA-approved targeted therapies. Here, we retrospectively compare BRAF-mutant AA and colorectal cancer (CRC). BRAF mutation is rare in AA (3%). Unlike CRC, BRAF V600E AA is not associated with poor prognosis, female s...
Saved in:
Main Authors: | Vinay K. Pattalachinti, Emaan Haque, Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Michael Overman, Christine M. Parseghian, Van K. Morris, Bryan Kee, Ryan W. Huey, Kanwal Raghav, Colin M. Court, John Paul Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-025-00821-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01) -
Correction: The landscape of BRAF transcript and protein variants in human cancer
by: Andrea Marranci, et al.
Published: (2025-02-01) -
Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
by: Michael Hoffmeister, et al.
Published: (2025-02-01) -
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
by: David Malka, et al.
Published: (2022-11-01) -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
by: Victoria Jennings, et al.
Published: (2022-03-01)